A randomized, double-blind study to compare tenoxicam with sustained release indomethacin in osteoarthritic patients treated in general practice.
A total of 144 patients were recruited for this randomized, double-blind study to compare the efficacy and tolerance of tenoxicam and sustained release indomethacin in patients with osteoarthritis. The results show that 20 mg/day tenoxicam is equal in efficacy to, and significantly better tolerated than, 75 mg/day sustained release indomethacin. Patients receiving tenoxicam recorded significantly better global tolerance ratings (P = 0.042) and fewer adverse events than those receiving indomethacin.
Hooper
P A
PA
Medical Department, Roche Products Ltd, Welwyn Garden City, UK.
O'Brien
K
K
Spence
S
S
D000328:Adult; D000368:Aged; D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003692:Delayed-Action Preparations; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D007213:Indomethacin / Q000627:therapeutic use*; D008297:Male; D008875:Middle Aged; D010003:Osteoarthritis / Q000188:drug therapy*; D010894:Piroxicam / Q000031:analogs & derivatives* / Q000627:therapeutic use; D011897:Random Allocation
D000894:Anti-Inflammatory Agents, Non-Steroidal; D003692:Delayed-Action Preparations; D010894:Piroxicam; D007213:Indomethacin; C032801:tenoxicam